Core Viewpoint - New Bridge Bio, established in 2016, is a global biotechnology platform company focused on developing innovative precision immuno-oncology drugs for cancer treatment, utilizing a new business model to enhance its drug pipeline through strategic collaborations and specialized subsidiaries [3][4]. Company Overview - New Bridge Bio primarily develops its proprietary drug, givastomig, a bispecific antibody targeting Claudin18.2 and 4-1BB, which is effective against various gastrointestinal malignancies including gastric, esophageal, and pancreatic cancers [3][4]. - The company aims to leverage its new business model to select and advance high-value therapeutic assets through dedicated subsidiaries, enhancing operational focus and risk management [3]. Product Details - Givastomig is designed to target tumors with low Claudin18.2 expression effectively and activates T-cells specifically at the tumor site, potentially reducing systemic side effects associated with traditional therapies [4]. - The global market for first-line treatments for gastric and esophageal adenocarcinoma (GEA), biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) is projected to grow significantly, with estimates of $8.9 billion, $1.8 billion, and $4.4 billion respectively by 2034 [5]. Clinical Development - New Bridge Bio has completed the Phase I clinical study and plans to initiate a randomized Phase II study in early 2026, having received no objections from the FDA regarding its clinical trial plans for givastomig [5]. - The company has established a pipeline that includes three clinical-stage projects, with two focused on oncology and one in ophthalmology [5]. Financial Performance - For the fiscal year 2023, New Bridge Bio reported total revenues of approximately -$202.12 million, with significant operating losses due to high research and administrative expenses [6]. - The company’s revenue from licensing and collaboration was recorded at $632,000 for 2023, with total expenses amounting to $72.65 million [6].

的申請版本 香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對 其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 NovaBridge Biosciences 新橋生物 （根據開曼群島法律註冊成立的有限公司） 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證 監會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。閣下閱覽本文件， 即代表閣下知悉、接納並向新橋生物（「本公司」）、其聯席保薦人、整體協調人、顧問或包 銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長 登記前，本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出 要約或邀請，有意投資者務請僅依據呈交香港公司註冊處註冊的本公司招股章程作出投資 決定；有關文本將於發售期內向公眾刊發。 52791 \ (Project Ion_Redacted) 00b. 警告_Red ...